Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Conference News HFSA 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

Yael L. Maxwell

October 01, 2025

News Daily News

ASNC Fighting Back Against Proposed Reimbursement Cuts for Amyloid Imaging

Yael L. Maxwell

September 11, 2025

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Todd Neale

May 19, 2025

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

Caitlin E. Cox

March 21, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2025

Shelley Wood

February 28, 2025

News Daily News

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Michael O'Riordan

February 13, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

Top Heart Failure News of 2024

Todd Neale

December 31, 2024

News Daily News

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

Yael L. Maxwell

December 12, 2024

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

L.A. McKeown

October 04, 2024

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

L.A. McKeown

August 30, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

News Daily News

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

L.A. McKeown

October 10, 2023

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

News Daily News

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

Caitlin E. Cox

July 19, 2023

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Advertisement

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

ASNC Fighting Back Against Proposed Reimbursement Cuts for Amyloid Imaging

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

TCTMD’s Top 10 Most Popular Stories for February 2025

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Top Heart Failure News of 2024

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Evoque and Patisiran: A Tale of Two Regulatory Journeys

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Carpal Tunnel Syndrome Again Tied to Heart Failure: German Data

ATTRibute-CM Top-Line Results Favorable for Acoramidis

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content